ISSN: 2455-5363
Global Journal of Infectious Diseases and Clinical Research
Research Article       Open Access      Peer-Reviewed

Meta-Analysis of Risk Factors for Development of Liver Cirrhosis in Chronic Hepatitis B Patients

Gaofeng Cai1, Yongdi Chen1* Li Li1*, Biao Zhou1*, Chonggao Hu1*, Yanhong Yu2, Mengxin Xu2, Qiaolu Hong2, Zhengting Wang1, Kui Liu1, Zhifang Wang1, Zhenggang Jiang1 and Jun Yao1

1Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China
2School of Medicine, Hangzhou Normal University, 16 Xuelin Road, Hangzhou 310018, China
*Corresponding author: Yongdi Chen, Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China, E-mail: ydchen@cdc.zj.cn

Li Li, Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China, E-mail: lli@cdc.zj.cn

Biao Zhou, Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China, E-mail: bzhou@cdc.zj.cn

Chonggao Hu, Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China, E-mail: chghu@cdc.zj.cn

DOI: 10.17352/2455-5363.000018
Received: 27 July, 2018 | Accepted: 27 August, 2018 | Published: 28 August, 2018
Keywords: Hepatitis B; Liver cirrhosis; Meta-analysis; Risk factor

Cite this as

Cai G, Chen Y, Li L, Zhou B, Chonggao Hu, et al. (2018) Meta-Analysis of Risk Factors for Development of Liver Cirrhosis in Chronic Hepatitis B Patients. Glob J Infect Dis Clin Res 4(2): 004-009. DOI: 10.17352/2455-5363.000018

Chronic hepatitis B virus (HBV) infection and chronic hepatitis C virus (HCV) are main reasons for the development of liver cirrhosis (LC) on a worldwide scale. Chronic HBV infection is a main reason for the development of LC in high-risk areas, for example, China and Africa, whereas chronic HCV infection is a main reason in developed countries. In China, the harm of LC is serious, and 30 million of chronic hepatitis B (CHB) patients is the major source of LC and the one-year cumulative incidence rate of LC in CHB patients was 2.1% - 6%. The risk factors of the development of LC in CHB patients reported were controversial.

Therefore, we took CHB as participants, and we searched for studies in Chinese Medical Journal Database, Pubmed, Elsevier, Springer, Wiley, OVID, and EBSCO via BoKu data service platform, and did a meta-analysis and evaluated whether those published risk factors changed the development risk of LC. Both odds ratio (OR) and mean difference (MD) with 95% confidence intervals (CI) were calculated by Review Manager 5.0.

In this meta-analysis, 2928cases and 6530controls from 29 studies were analyzed. The pooled OR with 95% CI for 5 factors analyzed were: drinking alcohol 1.32 (1.11, 1.59), cigarette smoking 1.26 (1.04, 1.52), hepatitis B e antigen (HBeAg) seropositivity 0.42 (0.19, 0.94), a family history of hepatitis B 1.95 (1.05, 3.62), and male gender 1.33 (1.08, 1.65), respectively. And the pooled MD with 95% CI for 6 factors analyzed were: serum aspartate aminotransferase/alanine aminotransferase (AST/ALT ) ratio 0.29(0.18,0.39), serum total bilirubin (TBil) levels 8.25(5.58,10.92)umol/L, duration of hepatitis B 2.68(2.21,3.15) years, age 7.37(4.60,10.14)years, serum alpha fetoprotein (AFP) levels -0.91(-16.04,14.22)ug/L, and serum HBV DNA levels 0.37 (-0.28, 1.02)copies/ml, respectively.

In CHB patients, habits of drinking alcohol and cigarette smoking, elevated serum levels of TBil and serum AST/ALT ratio, increased duration of hepatitis B, a family of hepatitis B, male gender and older age can increase the risk of LC development.

Abbreviations

HBV: Hepatitis B Virus; HBeAg: Hepatitis B e Antigen; HCV: Hepatitis C Virus; HCC: Hepatocellular Carcinoma; LC: Liver Cirrhosis; CHB: Chronic Hepatitis B; TBil: Total Bilirubin; AFP: Alpha Fetoprotein; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; CI: Confidence Intervals; MD: Mean Difference; CMJD: Chinese Medical Journal Database

Introduction

Chronic HBV infection and chronic HCV infection are main reasons for the development of LC and hepatocellular carcinoma (HCC) on a worldwide scale. Chronic HBV infection is a main reason for the development of LC and HCC in high-risk areas, for example, China and Africa, whereas chronic HCV infection is a main reason for the development of LC and HCC in developed countries, for example, the United States.

At present, chronic HBV infection is a serious threat to public health. According to the statistics, there were 2 billion people infected, and 360 million of these people are chronically infected [1]. In China, there are 120 million people infected, and 30 million of these people are CHB patients [2]. In long-term disease development of these chronic hepatitis B from one thing to another, chronic persistent infection of hepatitis B virus and recurrent inflammatory necrosis of the liver result in regeneration and repair, hepatic stellate cells activation, intrahepatic connective tissue dysplasia and a massive diffuse Extracellular matrix anomaly deposition, and result in Hepatic fibrosis and even LC.

In China, CHB patients are the major source of LC and the rate of chronic HBV infection in LC patients was 66% [3]. The one-year cumulative incidence rate of LC in CHB patients was 2.1% - 6% [4]. Fibrosis is the main intermediate link in the development of LC. At present, it is generally believed that liver fibrosis is reversible and reversal of fibrosis can prevent the progression of most chronic liver diseases, whereas LC is irreversible. Once LC occurs, the one-year cumulative incidence rate of decompensated LC was 10%, and the one-year cumulative incidence rate of HCC was 2%-7% [5]. Moreover, the risk of LC is enormous. The 5 - year survival rate of compensated LC was 80% - 86%, and the 5 - year survival rate of decompensated LC was low to 14% - 30% [6,7]. Therefore, we research risk factors of the development of LC in CHB patients to eliminate the risk factors for high-risk groups and to decrease or prevent the development of LC.

In CHB patients, hepatic inflammation, poor healthy behavior, and replication state of HBV were the major cause of the deterioration such as drinking alcohol, cigarette smoking, serum TBil levels, serum AST/ALT ratio, serum HBV DNA levels and so on. These indicators have been indicated the risk factors of LC development by previous studies, and these indicators also can be detected routinely by grassroots health institutions, however, the effects of these factors were controversial [8-36].

Meta-analysis can reduce random error and increase test power. In this study, we pooled both OR and MD with 95% CI for these factors to identify the associations between possible factors and the development of LC in CHB patients.

Materials and Methods

Literature and search strategy

All articles were retrieved from the following databases via BoKu data service platform: Chinese Medical Journal Database (CMJD), Pubmed, Elsevier, Springer, Wiley, OVID, EBSCO.

In search field, “MeSH Terms” were used to search, and the search terms (“hepatitis B”), (“liver cirrhosis”) and (“risk factor”) were used, and articles were published between January 2007 and January 2017.The present study was carried out following Meta-analysis in PRISMA guidelines [37].

Inclusion and exclusion criteria

Studies were included in this meta-analysis provided that: all eligible articles were retrospective study continuously or longitudinal study, and only primary studies published in English or in Chinese were included.

Studies were excluded from the meta-analysis provided that: (1) The article reported other forms of viral hepatitis (hepatitis C or D) as the etiological agent.(2) The article did not provide a workable value for the main variable.

Data extraction

To decide whether an article should be included or excluded, two independent reviewers carried out an assessment using a standardized data extraction form designed by our group. Data were extracted from each study by two separate investigators.

Discrepancies between the decisions of the two reviewers were discussed. If a consensus was not achieved, the decision was made by a third reviewer. Articles were examined to eliminate duplicate reports of the same research.

Statistical analysis

The OR or MD with 95% CI was used as the main outcomes to measure efficacy. Meta-analysis was performed using either the fixed-effect or random-effect model, depending on the statistical heterogeneity among studies as evaluated by Cochran’s chi-square test [38]. Statistical heterogeneity among studies was assessed using the Q and I2 statistics. The random-effect model was employed provided that P≤ 0.1, and the fixed effects model was employed provided that P>0.1. Analyses were performed using the software Review Manager 5.0 (Cochrane Collaboration, https://www.cc-ims.net/RevMan/relnotes.htm). The OR or MD wasn’t pooled when the number of OR of the risk factor were less than 5.

Results

Literature search

The selection of included studies in this meta-analysis was shown in figure 1. Twenty-seven eligible studies were identified after screening of 872 based on the inclusive and exclusive criteria.

Figure 1: Flowchart of the selection of studies for inclusion in this meta-analysis.

Characteristics of the studies

In this meta-analysis, 29 studies were included, and 2928 cases and 6530 controls from these studies were analyzed, including the OR or MD and their 95% CIs for risk factors, shown in figures 2-6. The characteristics of the studies, including number of reference, study region, study type, participants category for case/control, risk factors, sample size , male/ female and age (years), are shown in table 1.

Table 1: The characteristics of the studies.
Study  Region  Study Type Participants Category (Case/Control) Study Factors
15 SiChun, Luzhou retrospective study  LC/CHB HBV DNA,AST/ALT, male, age
21 China,
Tianjin 		retrospective study  LC/CHB TBil, HBeAg, age,
17 Taiwan,
Taipei		 Longitudinal study  LC/CHB HBeAg, male, cigarette smoking,
drinking alcohol
18 China,
Shanghai 		Longitudinal study  LC/CHB AST/ALT, AFP, age, duration of hepatitis B, HBeAg, HBV DNA, male, cigarette smoking, TBil, a family history of hepatitis B, drinking alcohol
27 Shanxi,
Xian 		retrospective study  LC/CHB Age, HBeAg
31 Shandong,
Lunan		 retrospective study  LC/CHB age, HBeAg, HBV DNA, male
19 China,
Guangxi 		retrospective study  LC/CHB AFP, age, male, cigarette smoking, TBil, drinking alcohol
24 Hebei,
Baoding 		retrospective study  LC/CHB AST/ALT, age, HBeAg, HBV DNA, male, TBil
35 Fujian,
Nanping 		retrospective study  LC/CHB AFP,HBV DNA,
20 China,
Beijing 		retrospective study  LC/CHB age, HBeAg, HBV DNA, male, TBil, drinking alcohol
25 China,
Guangxi 		retrospective study  LC/CHB AFP, age, male, cigarette smoking, TBil, drinking alcohol
28 China,
Xinjiang 		retrospective study  LC/CHB AFP, age, male, cigarette smoking, TBil, drinking alcohol
32 China,
Chongqing 		retrospective study  LC/CHB age, duration of hepatitis B, HBeAg, HBV DNA, male, a family history of hepatitis B, drinking alcohol
34 China,
Guangxi 		Longitudinal study  LC/CHB duration of hepatitis B, HBeAg, HBV DNA, male, a family history of hepatitis B
26 China,
Chongqing 		retrospective study  LC/CHB AST/ALT, age, HBeAg, HBV DNA, male,
9 Jiangxi,
Nanchang 		retrospective study  LC/CHB AST/ALT, age, HBV DNA,
14 China,
Beijing 		retrospective study  LC/CHB AST/ALT, age, HBeAg, HBV DNA, male
29 Hubei,
Wuhan 		retrospective study  LC/CHB age, HBV DNA, male, TBil
23 Guangxi,
Guilin 		retrospective study  LC/CHB age, HBV DNA, male, TBil,
13 China,
Shanghai 		retrospective study  LC/CHB age, HBV DNA, male, TBil
22 China,
Beijing 		retrospective study  LC/CHB age, HBV DNA, male, TBil
33 Guangdong,
Meizhou		 retrospective study  LC/CHB AFP,HBV DNA
30 Jiangxi,
jiujiang		 retrospective study  LC/CHB age, HBV DNA, male, TBil
11 Hubei,
shiyan		 retrospective study  LC/CHB age, HBV DNA, male, duration of hepatitis B, HBeAg
8 China,
shanghai		 retrospective study  LC/CHB age, AFP, male, HBeAg, TBil
12 Guangtong,
yangjiang		 retrospective study  LC/CHB age, HBV DNA, male, duration of hepatitis B, HBeAg
36 Guangxi,
nanning		 retrospective study  LC/CHB cigarette smoking, drinking alcohol
16 China,
shanghai		 Longitudinal study LC/CHB HBV DNA, male,
10 Hebei,
Shijiazhuang 		retrospective study  LC/CHB age, HBV DNA, ssmale

Effects of related factors on the development of LC

In this analysis, the effects of the following 11 factors were analyzed: drinking alcohol (7 studies, 4985 research objects), cigarette smoking (5 studies, 4217research objects), serum TBil levels (12 studies, 2336 research objects), serum AST/ALT ratio (5 studies, 917 research objects), serum HBV DNA levels (23 studies, 8187 research objects), HBeAg seropositivity (14 studies, 5827 research objects), serum AFP levels (4 studies, 861 research objects), a family history of hepatitis B (5 studies, 980 research objects), duration of hepatitis B (7 studies, 1359 research objects), age (24 studies, 5257 research objects), and gender (male) (24 studies, 8403 research objects), and the results are displayed in figures 2-6.

Figure 2: Effects of Related Factors on the Development of LC in CHB patients (enumeration data：G: drinking alcohol; H: cigarette smoking; I: a family history of hepatitis B).
Figure 3: Effects of Related Factors on the Development of LC in CHB patients (enumeration data：J: HBeAg seropositivity; K: gender (male)).
Figure 4: Effects of Related Factors on the Development of LC in CHB patients (measurement data：A: serum AFP levels; B: age).
Figure 5: Effects of Related Factors on the Development of LC in CHB patients (measurement data：C: duration of hepatitis B; D: serum HBV DNA levels).
Figure 6: Effects of Related Factors on the Development of LC in CHB patients (measurement data：E: serum AST/ALT ratio; F: serum TBil levels).

The pooled OR with 95% CI for 5 factors analyzed were: drinking alcohol 1.32 (1.11, 1.59), cigarette smoking 1.26 (1.04, 1.52), HBeAg seropositivity 0.42 (0.19, 0.94), a family history of hepatitis B 1.95 (1.05, 3.62), and male gender 1.33 (1.08, 1.65), respectively. The pooled MD with 95% CI for 6 factors analyzed were: serum AST/ALT ratio 0.29(0.18, 0.39), serum total bilirubin (TBil) levels 8.25(5.58,10.92)umol/L, duration of hepatitis B 2.68(2.21,3.15) years, age 7.37(4.60,10.14)years, serum alpha fetoprotein (AFP) levels -0.91(-16.04,14.22)ug/L, and serum HBV DNA levels 0.37 (-0.28, 1.02)copies/ml, respectively.

The heterogeneity test showed that the variation of study-specific OR or MD for serum HBV DNA levels, serum TBil levels, serum AST/ALT ratio, age, duration of hepatitis B, HBeAg seropositivity, a family history of hepatitis B and gender were statistically significant (p < 0.10), therefore, the effects for these factors were pooled via using the random effect method.

The heterogeneity test showed that the variation of study-specific OR or MD for the other factors were not statistically significant (p > 0.10), therefore, the effects for these factors were pooled via using the fixed effect method.

The analysis results of enumeration data shown in figures 2,3, and the analysis results of measurement data were shown in figures 4-6.

Publication bias

Articles published in the distribution is symmetrical and majority of the articles are in the funnel plot, and symmetrical axis is off center axis (OR=1) and is at the right side of the center axis. A funnel plot for publication bias is displayed in figure 7.

Figure 7: A funnel plot for publication distribution.

Discussion

Our meta-analysis demonstrated that, for CHB patients, elevated serum AST/ALT ratio and serum TBil levels, and increased duration of hepatitis B could significantly increase the risk of LC development. These findings also were confirmed by original studies [12,14,25,28]. In general, ALT is distributed in liver cell plasma, and AST is distributed in liver cells and mitochondria. In the early stages in CHB, serum ALT levels rise more than serum AST levels, but, in LC stage, liver cell damage is serious and mitochondria have also been severe damage, therefore, serum AST levels rise more than the ALT. Serum TBil levels is an important index to judge the damage degree of liver cell. All of above-mentioned hinted that decreasing liver damage could significantly decrease clinical course of CHB and decrease the number of LC development in CHB patients.

Our meta-analysis also demonstrated that, for CHB patients, drinking alcohol and cigarette smoking could significantly increase the risk of LC development. These findings also were confirmed by a meta-analysis of risk factors for development of HCC in similar subjects [39]. This result hinted that banning drink alcohol and cigarette smoking could decrease the number of LC development. The study’s result also showed a family history of hepatitis B, older age and male gender also could significantly increase the risk of LC development, and these results were existing facts.

Our meta-analysis result indicated that, HBeAg seropositivity can significantly decrease the risk of LC development, and this result was not easily understood or accepted, thus this will be an observation point for the future. Our meta-analysis result also indicated that, serum HBV DNA levels cannot significantly change the risk of LC development, and the result was different from the result in prospective cohort study [17], however, it was unknown that whether these were connected with that some patients had received antiviral treatment [40-42]. In future study, participants should be classified by antiviral treatment, but the study should meet the requirements of ethics.

This study has several limitations: (1) in subgroup analysis, the sample size for AFP was small. (2) There may be present some information recall bias in retrospective studies. (3) And only primary studies published in English or in Chinese were included. All of the points above may be a slight impact on this meta-analysis result.

Conclusion

In CHB patients, habits of drinking alcohol and cigarette smoking, elevated serum levels of TBil and serum AST/ALT ratio, increased duration of hepatitis B, a family of hepatitis B, male gender and older age can increase the risk of LC development.

We thanked Lu Shunshun for checking the data in Ningbo University.

Funding

This work was supported by National Natural Science Foundation of China (grant numbers No. 31500751, 2015) and Ministry of Science and Technology supporting the National Scientific and Technological Major Project of China (grant numbers No. 2013ZX10004–904, 2013).

Authors’ Contribution

Study design: G.C., B.Z., L.L.Y.C., C.H. Statistical analysis and interpretation: L.L., Y.C. Manuscript preparation: L.L., Zhi. W, J.Y., G.C., Z.J., Zhe.W, Y.Y, X.M., H.Q. Critical review of manuscript: B.Z., Y.C., C.H. All authors read and approved the final manuscript.

  1. Jury E (2003) International Consensus Conference on Hepatitis B 13-14 September 2002: Geneva Switzerland Consensus statement (short version) Journal of hepatology 38: 533-540. Link: https://tinyurl.com/y9x4m9fg
  2. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, et al. (2005) Study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chinese Journal of Epidemiology 26: 4. Link: https://tinyurl.com/yatedhpv
  3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) the contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 45: 529-538. Link: https://tinyurl.com/ybspd9sp
  4. Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Seminars in liver disease 26: 142-152. Link: https://tinyurl.com/ybxc5ecl
  5. Schuppan D, Afdhal NH (2008) Liver cirrhosis Lancet (London England) 371: 838-851. Link: https://tinyurl.com/yb2wwc4e
  6. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, et al. (1992) Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103: 1630-1635. Link: https://tinyurl.com/y8vk7a4r
  7. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, et al. (2002) Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97: 2886-2895. Link: https://tinyurl.com/y9fym3ru
  8. Cao YR, Peng LJ, YY OY, Wang JY, Guo JS (2013) Evaluation of the clinical risk factors associated with liver cirrhosis in patients with chronic hepatitis B viral infection. Chinese Hepatology 18: 211-215.
  9. Chen F, Xiao YQ, Chen CY, Tu XL (2009) Study on Relationship between Liver Pathological and Clinic Characteristics in Patients with Chronic Hepatitis B. Practical Clinical Medicine 10: 20-22. Link: https://tinyurl.com/yd87c83o
  10. Chen CY, Ning GX, Sun XL (2009) Comparison of the efficacy of lamivudine in the treatment of chronic hepatitis B and hepatitis B cirrhosis. Clinical Focus 24: 71-73. Link: https://tinyurl.com/yc4c5m2z
  11. Chen LL (2016) Study of clinical risk factors for incidence of cirrhosis in patients with chronic hepatitis B requiring hepatic functional protection treatment. Contemporary Medicine 22: 32-33. Link: https://tinyurl.com/yb9ttycg
  12. Hong YM, Huang XQ, Ye ZD, Yao ZG, Luo XX, et al. (2012) Analysis of risk factors for incidence of cirrhosis in patients with chronic hepatitis B requiring hepatic functional protection treatment. J Prat Med 4: 13-14.
  13. Hu CB, Gao Q, Tang JY (2013) Correlation between chronic hepatitis B and serum triglyceride and cholesterol levels. Chinese Journal of Infectious Diseases 31: 280-284. Link: https://tinyurl.com/y854aau8
  14. Jiang YY, Li HM, Wang RB (2008) Changes of chronic hepatitis B virus infection and T lymphocyte subsets. Journal of Chinese Medicine 43: 44-45. Link: https://tinyurl.com/ycm6umjs
  15. Li N, Zhang JJ (2013) Expression of Fox P 3 mRNA and the Serum level of IL – 12, IL –18 in Patients with Hepatitis B Cirrhosis. Academic dissertation 1.
  16. Liu LL, Wang JY, She WM (2008) Correlation between HBV-DNA and progress to cirrhosis in patients with chronic hepatitis B. Chinese Journal of Digestion 28: 742-745. Link: https://tinyurl.com/yd69r24e
  17. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL. (2013) Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 58: 546-554. Link: https://tinyurl.com/yapvogan
  18. Liu LL, Wang JY (2011) the risk factors of progression to cirrhosis with chronic hepatitis B. Fudan University 11.
  19. Liu YQ, Li S (2016) Association between catalase genetic variation and risk of chronic hepatitis B, HBV-liver cirrhosis and hepatocellular carcinoma. Guangxi Medical University 1. Link: https://tinyurl.com/ydejfnda
  20. Lu HY, Zeng Z, Tian D (2007) Clinical significance of alpha-fetoprotein detection in HBV infectious related diseases. Chinese Journal of Clinical Pharmacology and Therapeutics 12: 939-942.
  21. Pei YZ, Han T (2013) Changes of Hepatitis B Surface Antigen in the Progress of Hepatitis B - related Diseases. Tianjin Medical University 4. Link: https://tinyurl.com/y9pg7xwz
  22. Tan L, Zhao Y, Wang Y, Huang YX, Liu JH, et al. (2014) HBV-specific T lymphocyte responses during different stages of hepatitis B virus infection. Chinese Journal of Microbiology and Immunology 34: 863-867. Link: https://tinyurl.com/yako4r6g
  23. Qin YQ, Li XD, Liao H (2015) Comparative analysis of HBV pre-S deletion in chronically HBV-infected patients with different illness categories. Infectious Disease Information 28: 79-82.
  24. Shi RY, Zhen Z (2015) The role and clinical significance of serum IL-21 in patients with Chronic Hepatitis B cirrhosis and liver failure. Hebei Medical University 9.
  25. Su Y, Li CT, Liu YJ (2014) Risk factors causing cirrhosis to hepatitis B virus patients. Chin J Nosocomiol 24: 2500-2502.
  26. Tong J, Tong SW, Wang D, Zhang DZ, Tian YP (2011) Clinical Significance of Combined Detection of AST/ALT ratio and HBV Serological Markers in HBV Infected Patients. Labeled Immunoassays and Clinical Medicine 18: 7-11.
  27. Wang LC, Chen W, Yu Y (2012) Correlation of hepatitis B virus B and C genotypes with clincial manifestations of hepatitis B. Journal of Xi‘an University: Medical Sciences 2: 4. Link: https://tinyurl.com/y9n8peo4
  28. Wei QL (2015) Analysis of Risk Factors of Cirrhosis Caused in Patients with Chronic Hepatitis B. Seek Medical and Ask Medicine 5: 2.
  29. Xiao F, Ding HF, Ma K, Wu T, Ning Q (2012) Clinical study on evaluation of liver fibrosis by Fibroscan in patients with chronic hepatitis B. Journal of Internal Intensive Medicine 18: 83-85.
  30. Yang GZ (2014) The application of Fibroscan in patients with chronic hepatitis B. Mod Diagn Treat 25: 2331-2332.
  31. Zhang Y, Li Q (2012) The Assocation of Hepatitis B Virus Genotype and Basic Core Promote Mutations with Liver Cirrhosis and Hepatocellular Carcinoma Risks in Southern Shandong Province. Shandong University 4.
  32. Zhou X, Wang YM (2009) Role of HBV DNA level and genotype/subtype on pathogenesis of HBV-associated liver diseases. Third Military Medical University 3.
  33. Wu YL, Chen YX, Su LX, Wang XY (2014) Investigation of the Correlation of Variations of HBV-DNA Quantification and Alpha Fetal Protein Concentration in Serum with the Turnover of Hepatitis B Patients. China &Foreign Medical Treatment 33: 66-68. Link: https://goo.gl/8Jx7Y4  
  34. Xu JG, Zhang YX (2012) To analyze correlation factors effected on the outcome of chronic HBV infection. Xinjiang Medical University.
  35. Jiang MY, Zhang ZY, Hu WP, Wu QB (2010) Comparison of several biochemical and immunological indexes in patients with liver. Journal of China Traditional Chinese Medicine Information 2: 220-221.
  36. Lu Y, Bao JG, Deng Y (2015) Role of IL-18 Gene Promoter Polymorphisms, Serum IL-18 Levels, and Risk of Hepatitis B Virus-related Liver Disease in the Guangxi Zhuang Population: a Retrospective Case-Control Study. Asian Pac J Cancer Prev 16: 6019-6026.
  37. Key documents. Available online: https://www.prisma-statement.org/ (accessed on 11 January2017). Link: https://goo.gl/mYXa2i
  38. Dersimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled clinical trials 7: 177-188. Link: https://goo.gl/CJ33Tp
  39. Lyu X, Liu K, Chen Y, Wang Z, Yao J, et al (2016) Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis. Int J Environ Res Public Health 13: pii: E604. Link: https://goo.gl/3CteSU
  40. Li W, He GQ, Duan LF, Wei J, Yang WB (2009) Clinical characteristics of 1829 cases of HBeAg seropositivity chronic hepatitis B. Journal of Kunming medical university 3: 72-75.
  41. Mao JK, Li HY, Zhou Y (2002) A serological investigation on relationship between the infection rate of HBV and PHC. Practical Preventive Medicine 9: 608-610.
  42. Gao R, Liu ZJ, Chen F, Gao L, Jiang CW (2016) Mutiviate Regression Analysis of Risk Factors for HBV-related Primary Liver Cancer. J Clin Hepatol 30: 370-372. Link: https://tinyurl.com/ycmqhlct
© 2018 Cai G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Download as

Order for reprints


Article Alerts

Subscribe to our articles alerts and stay tuned.


Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License.

Help ?

Submit your next article Peertechz Publications, also join of our fulfilled creators. Submit a Manuscript

© Peertechz Publications Inc., 10880 Wilshire Blvd., Suite 1101, Los Angeles, California, 90024, USA